ACALABRUTINIB | ACALABRUTINIB | ATC L01EL02
ANTINEOPLASTIC BRUTON TYROSINE KINASE (BTK) INHIBITOR TREATMENT OF MANTLE CELL LYMPHOMA (MCL) FORM A COVALENT BOND WITH A CYSTEINE RESIDUE IN THE BTK ACTIVE SITE ACP-5862 IS THE MAJOR ACTIVE METABOLITE BUT ACTIVITY IS 50 PERCENT LESS POTENT | ORAL | Cmax 694 NANOMOLAR Tmax 0.75 HOUR F 25 PERCENT VD 34 LITER PPB 97.5 PERCENT Cl 159 LITER / HOUR HT 0.9 HOUR SOLUBILITY PRACTICALLY INSOLUBLE IN WATER AT PH VALUES ABOVE 6 | BRUTON TYROSINE KINASE (BTK) | Tyrosine-protein kinase BTK UNIPROT Q06187 BTK more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |